JP2009235073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009235073A5 JP2009235073A5 JP2009112258A JP2009112258A JP2009235073A5 JP 2009235073 A5 JP2009235073 A5 JP 2009235073A5 JP 2009112258 A JP2009112258 A JP 2009112258A JP 2009112258 A JP2009112258 A JP 2009112258A JP 2009235073 A5 JP2009235073 A5 JP 2009235073A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- polysorbate
- sodium starch
- starch glycolate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229950008882 Polysorbate Drugs 0.000 claims 3
- 229920000136 polysorbate Polymers 0.000 claims 3
- 229940079832 sodium starch glycolate Drugs 0.000 claims 2
- 239000008109 sodium starch glycolate Substances 0.000 claims 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims 2
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 claims 1
- 229960001021 Lactose Monohydrate Drugs 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229940068968 Polysorbate 80 Drugs 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000011236 particulate material Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 2
- 241000237942 Conidae Species 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Description
実施例32:
バッチサイズ:500g
1mgの式Iの化合物を含み、かつ4kPの平均硬度を有する70mgの錠剤を、上記の実施例16〜30のものと同様のパラメーターを使用して、下記の表に示した組成物で調製した:
バッチサイズ:500g
1mgの式Iの化合物を含み、かつ4kPの平均硬度を有する70mgの錠剤を、上記の実施例16〜30のものと同様のパラメーターを使用して、下記の表に示した組成物で調製した:
Claims (6)
- 前記ポリソルベートが前記医薬組成物の総重量に基づく重量の0.1〜1%の総量で存在する、請求項1に記載の医薬組成物。
- 前記ポリソルベートがポリソルベート80である、請求項1または2に記載の医薬組成物。
- カプセル形態である、請求項1〜3のいずれか1項に記載の医薬組成物。
- 錠剤形態である、請求項1〜3のいずれか1項に記載の医薬組成物。
- 肺動脈性高血圧症の治療に使用するための医薬の製造のための、請求項1〜5のいずれか1項に記載の医薬組成物の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2005/009775 | 2005-09-12 | ||
EP2005009775 | 2005-09-12 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008529767A Division JP4955685B2 (ja) | 2005-09-12 | 2006-09-11 | ピリミジン−スルファミドを含む安定な医薬組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009235073A JP2009235073A (ja) | 2009-10-15 |
JP2009235073A5 true JP2009235073A5 (ja) | 2012-03-29 |
JP5054061B2 JP5054061B2 (ja) | 2012-10-24 |
Family
ID=37865339
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008529767A Active JP4955685B2 (ja) | 2005-09-12 | 2006-09-11 | ピリミジン−スルファミドを含む安定な医薬組成物 |
JP2009112258A Active JP5054061B2 (ja) | 2005-09-12 | 2009-05-01 | ピリミジン−スルファミドを含む安定な医薬組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008529767A Active JP4955685B2 (ja) | 2005-09-12 | 2006-09-11 | ピリミジン−スルファミドを含む安定な医薬組成物 |
Country Status (24)
Country | Link |
---|---|
US (6) | US20080233188A1 (ja) |
EP (2) | EP2292209A3 (ja) |
JP (2) | JP4955685B2 (ja) |
KR (1) | KR101313395B1 (ja) |
CN (1) | CN101262847B (ja) |
AU (1) | AU2006290309B2 (ja) |
BR (1) | BRPI0615898B8 (ja) |
CA (1) | CA2621273C (ja) |
CY (1) | CY1113395T1 (ja) |
DK (1) | DK1928409T3 (ja) |
ES (1) | ES2393117T3 (ja) |
HK (1) | HK1121950A1 (ja) |
HR (1) | HRP20120957T1 (ja) |
IL (1) | IL190072A (ja) |
MY (1) | MY151003A (ja) |
NO (1) | NO341325B1 (ja) |
NZ (1) | NZ567188A (ja) |
PL (1) | PL1928409T3 (ja) |
PT (1) | PT1928409E (ja) |
RU (1) | RU2424805C2 (ja) |
SI (1) | SI1928409T1 (ja) |
TW (1) | TWI323661B (ja) |
WO (1) | WO2007031933A2 (ja) |
ZA (1) | ZA200802947B (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007031933A2 (en) | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
AR062501A1 (es) * | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
MX2010001837A (es) * | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
TWI441639B (zh) * | 2008-02-20 | 2014-06-21 | Actelion Pharmaceuticals Ltd | 用於治療卵巢癌之包含紫杉醇之組合 |
LT2315587T (lt) * | 2008-08-13 | 2018-01-10 | Actelion Pharmaceuticals Ltd. | Terapinės kompozicijos, turinčios macitentano |
WO2011019630A2 (en) | 2009-08-10 | 2011-02-17 | Board Of Regents, The University Of Texas System | Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors |
US10071059B2 (en) | 2009-12-18 | 2018-09-11 | Frieslandcampina Nederland Holding B.V. | Co-processed tablet excipient composition its preparation and use |
IT1403248B1 (it) * | 2010-11-12 | 2013-10-17 | Scharper Therapeutics Srl | Composizione per il trattamento di disfunzioni degli apparati fonatorio ed olfattorio |
EP2670405B1 (en) | 2011-02-04 | 2015-09-02 | Actelion Pharmaceuticals Ltd. | Combinations comprising macitentan for the treatment of glioblastoma multiforme |
DE14721256T1 (de) * | 2013-04-22 | 2017-03-16 | Sandoz Ag | Pharmazeutische zusammensetzungen mit kristallinem macitentan |
NZ753904A (en) | 2013-06-13 | 2020-07-31 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
CN105693624B (zh) * | 2013-06-14 | 2018-05-18 | 杭州普晒医药科技有限公司 | 马西替坦晶体及其制备方法、其药物组合物和用途 |
US20170158645A1 (en) * | 2014-07-15 | 2017-06-08 | Olon S.P.A. | Amorphous form and new crystalline forms of macitentan |
CN115364061A (zh) | 2014-07-25 | 2022-11-22 | 诺华股份有限公司 | C-met抑制剂的片剂制剂 |
CN105388244B (zh) * | 2015-12-10 | 2017-03-08 | 合肥久诺医药科技有限公司 | 一种马西替坦有关物质的高效液相色谱分析方法 |
WO2018153925A1 (en) | 2017-02-22 | 2018-08-30 | Amneal Pharmaceuticals Company Gmbh | Stable pharmaceutical compositions comprising macitentan |
SG11202105098VA (en) * | 2018-12-21 | 2021-06-29 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
TW202042818A (zh) * | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
CN114096239B (zh) * | 2019-07-05 | 2024-04-12 | 社会医疗技术员技术股份公司 | 压缩的马西替坦组合物、方法及其用途 |
CN114728002A (zh) | 2019-11-29 | 2022-07-08 | 埃科特莱茵药品有限公司 | 治疗肺动脉高血压的方法 |
WO2022238375A1 (en) | 2021-05-11 | 2022-11-17 | Actelion Pharmaceuticals Ltd | Methods of treating pulmonary hypertension |
TW202317119A (zh) * | 2021-06-11 | 2023-05-01 | 瑞士商艾克泰聯製藥有限公司 | 用於口服投予之分散錠 |
CN117835971A (zh) | 2021-08-25 | 2024-04-05 | 巴斯夫欧洲公司 | 直接压片用辅料组合物 |
WO2023038600A1 (en) * | 2021-09-07 | 2023-03-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A capsule formulation comprising macitentan |
EP4154873A1 (en) | 2021-09-22 | 2023-03-29 | Sanovel Ilac Sanayi Ve Ticaret A.S. | The tablet comprising macitentan |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
JPH04103525A (ja) | 1990-08-22 | 1992-04-06 | Sanwa Kagaku Kenkyusho Co Ltd | 難水溶性薬物の持続性製剤化方法 |
RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
JP3905921B2 (ja) | 1992-10-02 | 2007-04-18 | ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー | 凝固第▲viii▼因子を含む組成物及びその製造方法並びに安定剤としての界面活性剤の使用方法 |
US5811120A (en) | 1994-03-02 | 1998-09-22 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
CN1102580C (zh) | 1995-12-20 | 2003-03-05 | 山之内制药株式会社 | 芳基乙烯基磺酰胺衍生物及其医药组合物 |
JPH103525A (ja) | 1996-06-14 | 1998-01-06 | Dainippon Printing Co Ltd | Icカード、命令コード格納方法及び命令コード実行方法 |
AR017426A1 (es) | 1997-12-08 | 2001-09-05 | Smithkline Beecham Corp | Sal de monoargininilo del acido (e)-3-[1-n-butil-5-[2-(2-carboxifenil)metoxi-4-clorofenil]-1h-pirazol-4-il]-2-[(5-metoxi-2,3-dihidrobenzofuran-6-il)metil]-prop-2-enoico, composicion farmaceutica que la contiene, su uso para la manufactura de un medicamento y procedimiento para su preparacion |
AU741992B2 (en) | 1998-03-06 | 2001-12-13 | Adare Pharmaceuticals S.R.L. | Fast disintegrating tablets |
US20010014352A1 (en) * | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
US20040062803A1 (en) * | 1999-12-22 | 2004-04-01 | Hedden David B. | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
AU2464301A (en) * | 1999-12-31 | 2001-07-16 | Encysive Pharmaceuticals Inc. | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
JP2001335469A (ja) | 2000-05-26 | 2001-12-04 | Lion Corp | 固体製剤の製造方法 |
KR20080064908A (ko) | 2000-06-28 | 2008-07-09 | 테바 파마슈티컬 인더스트리즈 리미티드 | 카르베딜올 |
JP4334869B2 (ja) | 2000-12-01 | 2009-09-30 | 協和発酵キリン株式会社 | 溶解性または経口吸収性の改善された組成物 |
KR20030059835A (ko) | 2000-12-07 | 2003-07-10 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 관상동맥 질환 또는 동맥경화증에 대한 abca-1 상승화합물로서의 1,3,5-트리아진 및 피리미딘 |
EP1693372A1 (en) * | 2000-12-18 | 2006-08-23 | Actelion Pharmaceuticals Ltd. | Novel Sulfamides and their use as endothelin receptor antagonists |
FR2819720B1 (fr) * | 2001-01-22 | 2004-03-12 | Fournier Lab Sa | Nouveaux comprimes de fenofibrate |
JP3930290B2 (ja) | 2001-09-12 | 2007-06-13 | 富士フイルム株式会社 | 熱現像感光材料及びそれを用いた熱現像方法 |
KR20030041577A (ko) * | 2001-11-20 | 2003-05-27 | 디디에스텍주식회사 | 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물 |
BR0306726A (pt) * | 2002-01-07 | 2004-12-21 | Pharmacia Corp | Mistura de fármacos com melhor taxa de dissolução |
MXPA04007737A (es) | 2002-02-11 | 2004-10-15 | Pfizer | Derivados de nicotinamida utiles como inhibidores de fosfodesterasas 4. |
PL208114B1 (pl) | 2002-02-26 | 2011-03-31 | Astrazeneca Ab | Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie |
GB0204771D0 (en) | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Fast disintegrating tablets |
WO2004067008A1 (ja) | 2003-01-28 | 2004-08-12 | Takeda Pharmaceutical Company Limited | 受容体作動薬 |
CA2512663A1 (en) | 2003-02-25 | 2004-09-10 | Eli Lilly And Company | Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride |
KR20070015506A (ko) | 2003-12-10 | 2007-02-05 | 액티브 바이오틱스 인코포레이티드 | 리파마이신 유사체 및 그의 용도 |
US7094081B1 (en) * | 2005-03-24 | 2006-08-22 | Delphi Technologies, Inc. | Electrical connector assembly |
WO2007031933A2 (en) | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
TWI441639B (zh) | 2008-02-20 | 2014-06-21 | Actelion Pharmaceuticals Ltd | 用於治療卵巢癌之包含紫杉醇之組合 |
LT2315587T (lt) | 2008-08-13 | 2018-01-10 | Actelion Pharmaceuticals Ltd. | Terapinės kompozicijos, turinčios macitentano |
EP2670405B1 (en) | 2011-02-04 | 2015-09-02 | Actelion Pharmaceuticals Ltd. | Combinations comprising macitentan for the treatment of glioblastoma multiforme |
-
2006
- 2006-09-11 WO PCT/IB2006/053210 patent/WO2007031933A2/en active Application Filing
- 2006-09-11 DK DK06809280.8T patent/DK1928409T3/da active
- 2006-09-11 US US12/066,448 patent/US20080233188A1/en not_active Abandoned
- 2006-09-11 KR KR1020087008450A patent/KR101313395B1/ko active IP Right Review Request
- 2006-09-11 MY MYPI20080524 patent/MY151003A/en unknown
- 2006-09-11 EP EP10009910A patent/EP2292209A3/en not_active Withdrawn
- 2006-09-11 AU AU2006290309A patent/AU2006290309B2/en active Active
- 2006-09-11 RU RU2008113869/15A patent/RU2424805C2/ru active
- 2006-09-11 BR BRPI0615898A patent/BRPI0615898B8/pt active IP Right Grant
- 2006-09-11 NZ NZ567188A patent/NZ567188A/en unknown
- 2006-09-11 CN CN2006800333751A patent/CN101262847B/zh active Active
- 2006-09-11 PT PT06809280T patent/PT1928409E/pt unknown
- 2006-09-11 EP EP06809280A patent/EP1928409B1/en active Active
- 2006-09-11 SI SI200631471T patent/SI1928409T1/sl unknown
- 2006-09-11 PL PL06809280T patent/PL1928409T3/pl unknown
- 2006-09-11 ES ES06809280T patent/ES2393117T3/es active Active
- 2006-09-11 JP JP2008529767A patent/JP4955685B2/ja active Active
- 2006-09-11 CA CA2621273A patent/CA2621273C/en active Active
- 2006-09-12 TW TW095133695A patent/TWI323661B/zh active
-
2008
- 2008-03-11 IL IL190072A patent/IL190072A/en active IP Right Grant
- 2008-04-03 ZA ZA200802947A patent/ZA200802947B/xx unknown
- 2008-04-09 NO NO20081724A patent/NO341325B1/no unknown
-
2009
- 2009-02-18 US US12/388,142 patent/US8367685B2/en active Active
- 2009-03-09 HK HK09102261.9A patent/HK1121950A1/xx not_active IP Right Cessation
- 2009-05-01 JP JP2009112258A patent/JP5054061B2/ja active Active
-
2012
- 2012-11-21 CY CY20121101126T patent/CY1113395T1/el unknown
- 2012-11-23 HR HRP20120957TT patent/HRP20120957T1/hr unknown
-
2013
- 2013-01-08 US US13/736,699 patent/US9265762B2/en active Active
-
2016
- 2016-01-20 US US15/002,255 patent/US10117870B2/en active Active
-
2018
- 2018-02-20 US US15/900,586 patent/US10946015B2/en active Active
-
2020
- 2020-12-09 US US17/116,983 patent/US11648249B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009235073A5 (ja) | ||
JP5714492B2 (ja) | 粒状体、それらの調製方法、およびそれらを含む医薬品 | |
TWI407978B (zh) | 濕粒狀藥物之製備方法 | |
JP2014167026A5 (ja) | ||
JP5173794B2 (ja) | Src/abl阻害剤 | |
JP2014237658A5 (ja) | ||
HRP20151383T1 (hr) | Farmaceutski pripravci koji sadrže nilotinib ili njegovu sol | |
JP5714600B2 (ja) | 共加工された錠用賦形剤混合物、その調製及び使用 | |
JP5991968B2 (ja) | トルバプタン固形分散剤及びその製造方法 | |
EP3606511B1 (en) | Pharmaceutical composition comprising lenvatinib mesylate | |
JP2006514100A5 (ja) | ||
JP2009501214A (ja) | クロピドグレルビスルファートを含有する薬学的組成物 | |
JP2019108324A (ja) | リバーロキサバン含有医薬組成物 | |
JP6302802B2 (ja) | カルシウム拮抗薬/アンジオテンシンii受容体拮抗薬含有医薬製剤の製造方法 | |
JP5575114B2 (ja) | シュウ酸エスシタロプラムを含む粒状物 | |
WO2020070147A1 (en) | Pharmaceutical composition comprising lenvatinib esylate or tosylate | |
JP2010202579A (ja) | アカルボースを含有する口腔内崩壊剤 | |
JP5241511B2 (ja) | 溶出性の改善された医薬組成物 | |
CN103989652A (zh) | 酒石酸美托洛尔缓释制剂及其制备方法 | |
KR101817714B1 (ko) | 발사르탄을 포함하는 경구용 고형 제제 | |
JP7101464B2 (ja) | アジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤の品質向上方法、並びにアジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤及びその製造方法 | |
CN105636581A (zh) | 药物组合物 | |
JP2020147542A (ja) | ダビガトランエテキシラートまたはその薬学的に許容される塩を含有する多層錠 | |
JP6199922B2 (ja) | 化学的な安定性が向上したイルベサルタン含有錠剤 | |
KR20180060705A (ko) | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제 |